N-tert-butyl-N,4,4-trimethylpentan-1-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-tert-butyl-N,4,4-trimethylpentan-1-amine
• 化学式: C₁₂H₂₇N
• 分子量: 185.35
• InChiKey: LWWCXJJYAQTYFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• FLUORESCENT COMPOUNDS AND USES THEREOF
  申请人：BIOTIUM, INC.

  公开号：US20160024067A1

  公开（公告）日：2016-01-28

  The invention provides compounds, including fluorescent nucleic acid dyes, and methods for use including nucleic acid detection, nucleic acid amplification reactions, and high-resolution melt curve analysis. Further provided are kits, instruments and systems comprising compounds of the invention or adapted for use with compounds of the invention or other nucleic acid dyes.

  这项发明提供了化合物，包括荧光核酸染料，以及用于核酸检测、核酸扩增反应和高分辨率熔解曲线分析的方法。还提供了包含该发明化合物或适用于与该发明化合物或其他核酸染料一起使用的试剂盒、仪器和系统。
• Nitrogen ring linked deoxyuridine triphosphatase inhibitors
  申请人：CV6 Therapeutics (NI) Limited

  公开号：US10829457B2

  公开（公告）日：2020-11-10

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

  本文提供了 dUTP 酶抑制剂、包含此类化合物的组合物以及使用此类化合物和组合物的方法。
• Hydantoin containing deoxyuridine triphosphatase inhibitors
  申请人：CV6 Therapeutics (NI) Limited

  公开号：US11014924B2

  公开（公告）日：2021-05-25

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

  本文提供了dUTP酶抑制剂、包含这些化合物的组合物以及使用这些化合物和组合物的方法。
• Uracil containing compounds
  申请人：CV6 Therapeutics (NI) Limited

  公开号：US11247984B2

  公开（公告）日：2022-02-15

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

  本文提供了 dUTP 酶抑制剂、包含此类化合物的组合物以及使用此类化合物和组合物的方法。
• METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS
  申请人：NOVARTIS AG

  公开号：US20140134262A1

  公开（公告）日：2014-05-15

  The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R 1 , X 1 , R 7 , R 5 , C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.